Axon raises $1B in zero-coupon convertible notes as shares slide 10%
What’s the deal? Axon has launched a registered offering of $1 billion in zero-coupon convertible senior notes due September 15, 2031. Underwriters hold an option to buy an extra $150 million.
The terms: The notes are unsecured, accrue no periodic interest, and can be settled at Axon’s choice in cash, common stock, or a mix of both.
Where the money goes: Axon will use part of the proceeds to buy capped calls meant to limit dilution when the notes convert, and the rest for general corporate purposes, including growth and possible acquisitions.
Why now? Alongside the offering, Axon amended its revolving credit facility, raising it from $300 million to $500 million with a $150 million accordion. Interest runs at SOFR plus 1.25–1.75%, with new leverage and coverage covenants that hinge on the note sale closing.
The market’s take: Investors pushed AXON down roughly 10% in the same trading session. Analysts kept a Buy rating with an $825 price target.
What could go wrong? Watch the capped-call sizing, the potential for share dilution if the notes convert, and the covenant tests tied to SOFR.
The signal: At $1 billion, the raise ranks in the 93rd percentile among post-IPO convertible rounds in the United States, based on 781 comparable deals. The zero-coupon structure lets Axon secure large-scale capital without periodic interest, while the capped calls signal a focus on protecting existing shareholders from dilution.
Read more: particle.news
Image credit: Generated with Gemini
